Industry
Fidson Healthcare Records ₦17.79bn Pre-Tax Profit in Nine Months, Up 49.47%
Fidson Healthcare Plc reported a 49.47% increase in profit before tax to ₦17.79 billion for the nine months ended 30 September 2026, as revenue rose to ₦112.61 billion from ₦93.08 billion in the corresponding period of 2025.
Fidson Healthcare Plc has reported a 49.47% increase in profit before tax to ₦17.79 billion for the nine months ended 30 September 2026, supported by higher revenue and operating profit, according to the pharmaceutical manufacturer's unaudited financial statements.
The company recorded revenue of ₦112.61 billion during the nine-month period, representing an increase of 21.00% from ₦93.08 billion reported in the corresponding period of 2025.
Profit before tax rose from ₦11.90 billion in January–September 2025 to ₦17.79 billion in the same period of 2026, while profit for the period increased by 47.20% to ₦11.74 billion from ₦7.97 billion.
Revenue Growth Across Product Segments
Fidson's financial statements show that ethical products remained its largest revenue contributor, generating ₦69.19 billion during the nine months, compared with ₦61.14 billion in the corresponding period of 2025.
Revenue from over-the-counter (OTC) products increased to ₦35.05 billion from ₦27.82 billion, while consumer healthcare products generated ₦6.39 billion, up from ₦3.76 billion.
Export revenue also rose to ₦1.98 billion from ₦364.64 million in the corresponding period of 2025.
Revenue earned in Nigeria amounted to ₦110.63 billion, compared with ₦92.72 billion in the previous year's corresponding period.
Operating Profit and Finance Costs
Gross profit increased to ₦48.94 billion from ₦38.21 billion, while operating profit rose to ₦21.24 billion from ₦16.95 billion.
However, administrative expenses increased to ₦16.42 billion from ₦9.91 billion, while selling and distribution expenses rose to ₦11.51 billion from ₦7.66 billion.
Finance costs declined to ₦3.73 billion from ₦5.14 billion, contributing to the improvement in profit before tax. The company also recorded a net exchange loss of ₦104.28 million, substantially lower than the ₦4.16 billion reported for the corresponding period of 2025.
Income tax provision increased to ₦6.05 billion from ₦3.93 billion.
Assets, Inventory and Borrowings
As at 30 September 2026, Fidson's total assets stood at ₦125.41 billion, compared with ₦80.29 billion at 31 December 2025.
Property, plant and equipment increased to ₦39.05 billion from ₦30.94 billion, while inventories rose to ₦36.96 billion from ₦26.55 billion.
Cash and bank balances increased to ₦10.93 billion from ₦4.71 billion at the end of 2025.
The company's total interest-bearing loans and borrowings rose to ₦23.85 billion from ₦14.00 billion at 31 December 2025. Trade and other payables also increased to ₦30.35 billion from ₦6.63 billion.
Shareholders' Equity and Earnings Per Share
Total equity increased to ₦60.01 billion as at 30 September 2026, compared with ₦30.20 billion at the end of 2025.
Basic earnings per share rose to 391 kobo from 347 kobo in the corresponding nine-month period of 2025.
The financial statements also recorded ₦3.60 billion in dividends paid during the period, compared with ₦2.29 billion in the previous year.
Financial Reporting
The unaudited financial statements cover the nine months ended 30 September 2026, with comparative figures for the corresponding period of 2025. They were signed on behalf of the company's board of directors on 22 October 2026 by Managing Director and Chief Executive Officer Abiola Adebayo and Finance Director Imokha Ayebae.
The results provide a financial overview of Fidson's revenue growth, profitability, operating expenses and financial position during the first nine months of 2026.
Source: Fidson Healthcare Plc, Unaudited Financial Statements for the Period Ended 30 September 2026.
More like this
Muonemeh Highlights Regional Regulatory Cooperation at NPME2026
26 Oct 2026
Nigeria Targets West Africa's 460 Million Medicines Market as FG Set to Commission 11 Pharmaceutical Manufacturing Projects
18 Jul 2026
NAFDAC Debunks Claims That Camosunate Has Been Banned in Nigeria
21 Nov 2026